Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beyond Air, Inc. filings document the regulatory record for a commercial-stage nitric oxide medical device and biopharmaceutical company. Proxy materials cover stockholder votes on charter amendments, reverse stock-split authority, director elections, auditor ratification, and equity incentive plan share reserves.
Form 8-K disclosures record material events such as executive officer transitions, separation agreements, Nasdaq continued-listing compliance notices, annual meeting results, material agreements, capital-structure matters, operating and financial results, and clinical or regulatory disclosures tied to the company's nitric oxide programs.
Beyond Air, Inc. appointed Denton "Duke" Dewrell as its principal financial officer and principal accounting officer on December 8, 2025.
Dewrell, age 39, has been the company’s Global Controller since April 2025, after serving as U.S. Controller from August 2024 and as Head of Finance and Controller of Beyond Cancer Ltd., a majority owned subsidiary, since August 2023.
He previously held senior finance roles at Updater Inc. and spent more than ten years in public accounting at Ernst & Young LLP. In his new role, he will continue to receive base compensation of $260,000 per year and participate in Beyond Air’s and Beyond Cancer’s equity incentive plans.
Beyond Air, Inc. (XAIR) reported an insider equity change for a director on Form 4. On November 4, 2025, the Board approved an option repricing effective that same day, reducing the exercise price of multiple stock option grants to $1.95 per share, which matches the closing price of Beyond Air’s common stock on November 3, 2025.
The filing shows that previously granted stock options with higher exercise prices, including options priced at $10.80 and $5.892 per share, were adjusted to the new $1.95 level. All other terms of the options, such as the number of underlying shares and expiration dates, remain unchanged.
The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan. They continue to vest according to the original vesting schedules set out in the award agreements, contingent on the reporting person’s continued service with Beyond Air on the applicable vesting dates.
Beyond Air, Inc. (XAIR) filed a Form 4 reporting that its Chief Operating Officer had existing stock options repriced. On November 4, 2025, the Board of Directors approved an option repricing, effective the same day, reducing the exercise price of several option grants to $1.95 per share, which was the closing price of Beyond Air’s common stock on November 3, 2025. All other terms of the options, including the number of shares and expiration details, remain unchanged.
The options were granted under the company’s Amended and Restated 2013 Equity Incentive Plan. They become exercisable based on the vesting schedule in the original award agreements, which continue to require the reporting person’s ongoing service with the company on each vesting date.
Beyond Air, Inc. has filed a Form S-1 to register the resale of up to 1,600,000 shares of common stock that may be issued to Streeterville Capital, LLC under an Equity Purchase Agreement. These shares, called Put Shares, will be issued over time at prices tied to the market price of XAIR stock, and Streeterville will act as an underwriter in reselling them.
The company may sell common stock to Streeterville for cash or, after certain offset events, by cancelling amounts outstanding under a $12,050,000 secured promissory note. Beyond Air may receive up to $20,000,000 in gross proceeds from sales of shares to Streeterville, but it will receive no proceeds from Streeterville’s resale of the registered shares. As of November 20, 2025, Beyond Air had 8,009,488 shares of common stock outstanding. The equity line is subject to a 4.99% beneficial ownership cap and Nasdaq’s 19.99% share issuance limitation.
Beyond Air (XAIR) reported Q2 FY2026 results. Revenue was $1.8 million, up from $0.8 million a year ago, but cost of revenues of $2.1 million produced a gross loss of $0.3 million. Operating expenses were $7.4 million, leading to a loss from operations of $7.7 million and a net loss of $8.3 million (basic and diluted loss per share $1.25).
Cash, cash equivalents, marketable securities and restricted cash totaled $10.9 million as of September 30, 2025. The company raised $8.1 million via its ATM program and received $2.9 million from warrant exercises during the six months. Long‑term debt, net, was $10.1 million, and management disclosed that recent results and projected cash outflows raise “substantial doubt” about the ability to meet obligations without additional financing.
The LungFit PH leasing business recognized $1.4 million in revenue in the quarter, and minimum future lease payments contracted total $11.1 million through 2029. Shares outstanding were 8,009,488 as of November 7, 2025; this is a baseline figure, not the amount being offered.
Beyond Air (XAIR) reported an insider equity update: a director’s outstanding stock options were repriced by the board to an exercise price of $1.95 per share, effective November 4, 2025. The new price matches the closing price on November 3, 2025, and all other terms, including vesting, remain unchanged under the company’s Amended and Restated 2013 Equity Incentive Plan.
The filing lists multiple option grants adjusted from prior exercise prices of $10.80 and $5.892 to $1.95, with representative tranches of 10,000, 4,500, 2,000, 1,500, and 1,250 options now reflecting the revised strike price.
Beyond Air, Inc. (XAIR) director reported warrant transactions on Form 4. In connection with a $2,000,000 loan to the company, the reporting person acquired warrants to purchase up to 512,821 shares at $1.95. Separately, an outstanding warrant for 494,332 shares at $7.586 was cancelled and a replacement warrant for 494,332 shares at $1.95 was issued. The warrants are exercisable on or after issuance and expire five years from their respective issuance dates.
Beyond Air, Inc. (XAIR) disclosed a director Form 4 reflecting a board-approved option repricing. On November 4, 2025, the board reduced the exercise price of certain outstanding stock options to $1.95 per share, which was the closing price of the company’s common stock on November 3, 2025.
The Form 4 shows multiple option awards previously carrying exercise prices of $10.80 and $5.892, each adjusted to $1.95. The company states that all other terms of the options remain unchanged. These options were granted under the Amended and Restated 2013 Equity Incentive Plan and continue to follow their existing vesting schedules, subject to the director’s continued service.
Beyond Air (XAIR) reported insider activity on a Form 4 detailing an option repricing for its Chief Financial Officer effective November 4, 2025. The exercise price of certain stock options was reduced to $1.95 per share, the closing price of the company’s common stock on November 3, 2025. All other terms of the options remain unchanged.
The filing shows cancellations of options previously priced at $10.80 and $5.892 and grants at $1.95 in equivalent amounts, including 15,000, 6,000, 3,750, 1,000, and 17,500 options. Following the reported transactions, the CFO beneficially owns 47,500 derivative securities directly. The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan and will vest per the original award agreements, subject to continued service.
Beyond Air, Inc. (XAIR) reported a Form 4 showing an option repricing approved by its Board on November 4, 2025. The exercise price of certain director stock options was reduced to $1.95 per share, which was the closing price of the company’s common stock on November 3, 2025. All other terms of the options remain unchanged.
The filing reflects paired transactions where options previously carrying a $10.80 exercise price were disposed and corresponding options with a $1.95 exercise price were acquired. Table entries include examples of 187 option units repriced per line item. The options were granted under the company’s Amended and Restated 2013 Equity Incentive Plan and continue to vest as previously reported, subject to the reporting person’s continued service.